7.04
0.57%
+0.04
Nanobiotix ADR stock is currently priced at $7.04, with a 24-hour trading volume of 1,109.
It has seen a +0.57% increased in the last 24 hours and a +20.55% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $6.96 pivot point. If it approaches the $7.07 resistance level, significant changes may occur.
Previous Close:
$7.00
Open:
$7.13
24h Volume:
1,109
Market Cap:
$331.66M
Revenue:
$27,600
Net Income/Loss:
$-62.02M
P/E Ratio:
-3.9725
EPS:
-1.7722
Net Cash Flow:
$-39.23M
1W Performance:
+6.67%
1M Performance:
+20.55%
6M Performance:
+25.60%
1Y Performance:
+53.71%
Nanobiotix ADR Stock (NBTX) Company Profile
Name
Nanobiotix ADR
Sector
Industry
Phone
33 1 40 26 04 70
Address
60 rue de Wattignies, Paris
Nanobiotix ADR Stock (NBTX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-06-21 | Initiated | Evercore ISI | Outperform |
Nanobiotix ADR Stock (NBTX) Latest News
Earnings call: Nanobiotix reports Q1 2024 results, advances with NBTXR3 - Investing.com India
Investing.com India
NANOBIOTIX Co-Founder and CEO Laurent Levy Named to 2022 PharmaVoice 100 List of Most Inspiring People in ... - The Globe and Mail
The Globe and Mail
Nanobiotix Announces Latest Share and Voting Rights Update - TipRanks.com - TipRanks
TipRanks
Nanobiotix Prepares to Unveil Q1 2024 Results - TipRanks.com - TipRanks
TipRanks
Nanobiotix's NBTXR3 Enters Phase 2 Lung Cancer Study - TipRanks.com - TipRanks
TipRanks
Nanobiotix's Revenue at Risk: The High Stakes of Sole Dependence on Janssen Partnership - TipRanks.com - TipRanks
TipRanks
Nanobiotix ADR Stock (NBTX) Financials Data
Nanobiotix ADR (NBTX) Revenue 2024
NBTX reported a revenue (TTM) of $27.60 thousand for the quarter ending June 30, 2021.
Nanobiotix ADR (NBTX) Net Income 2024
NBTX net income (TTM) was -$62.02 million for the quarter ending June 30, 2023, a -18.86% decrease year-over-year.
Nanobiotix ADR (NBTX) Cash Flow 2024
NBTX recorded a free cash flow (TTM) of -$39.23 million for the quarter ending June 30, 2023, a -9.77% decrease year-over-year.
Nanobiotix ADR (NBTX) Earnings per Share 2024
NBTX earnings per share (TTM) was -$1.7722 for the quarter ending June 30, 2023, a -9.33% decline year-over-year.
About Nanobiotix ADR
Nanobiotix SA operates as a clinical-stage nanomedicine company for the treatment of cancer worldwide. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. It offers NBTXR3, a radio-enhancer hafnium oxide for the treatment of solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, and other cancers. Nanobiotix SA was incorporated in 2003 and is headquartered in Paris, France.
Cap:
|
Volume (24h):